Life sciences organizations now manage all quality control data and processes
in one solution for greater efficiency and speed <\/i><\/p>\n
BARCELONA, Spain \u2014 22 Aug. 2024 \u2014 <\/strong> Veeva Systems<\/a> (NYSE: VEEV) today announced increasing momentum for Veeva Vault LIMS<\/a>, a modern cloud solution that simplifies end-to-end quality control (QC) business processes. Vault LIMS is unified with Veeva Vault Quality<\/a>, enabling customers to share data and content across quality applications for more informed batch release decisions.<\/p>\n \u201cAdopting Veeva Vault LIMS to replace a paper-based documentation practice will streamline method execution and minimize documentation errors so we can deliver more value to clients,\u201d said Andrew Laughhunn, senior director of QC analytical testing at Forge Biologics. \u201cThe time and effort we can refocus on other priorities is exciting, along with the cost savings we will accrue. Using a modern LIMS, we can focus on testing, the results, and the science.\u201d<\/p>\n With Vault LIMS, customers are bringing together quality assurance (QA) and QC to improve efficiency, compliance, and right first time execution. By establishing a seamless quality workflow, companies optimize QC to drive test reliability and accuracy while reducing cycle times.<\/p>\n \u201cVeeva Vault LIMS can significantly streamline lab operations by consolidating the numerous systems, paper processes, and spreadsheets currently used to manage QC into one application,\u201d said Jason Boyd, senior director, Veeva Vault LIMS. \u201cWe\u2019ve worked closely with our early adopters to deliver a seamless user experience that simplifies QC processes, bringing greater productivity and speed to the manufacturing lab and virtual organizations leveraging partners.\u201d<\/p>\n For established organizations and fast-growing biotechs, Vault LIMS delivers a complete QC management and test execution solution that can be deployed quickly. This reduces the reliance on IT teams and lowers the total cost of ownership, making the adoption of an advanced LIMS easier for the business.<\/p>\n “Market dynamics and pricing pressures are compelling life sciences organizations to enhance operational efficiencies. Manufacturing QC organizations can play a crucial role in driving improvements by optimizing batch release testing,” said Daniel R. Matlis, president of Axendia, Inc., a leading life sciences analyst and strategic advisory firm. “Veeva’s LIMS application offers a dynamic, cloud-first solution that can be utilized by established biopharma organizations aiming to build capacity, as well as emerging companies looking to scale.”<\/p>\n Additional Information<\/strong> About Veeva Systems<\/strong> Veeva Forward-looking Statements<\/strong> ###<\/p>\n
\nLearn more on Veeva Vault LIMS, visit: veeva.com\/eu\/VaultLIMS<\/a>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a><\/p>\n
\nVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2024, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 35 and 36), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n